How Many IntelliPharmaCeutics International Inc. (NASDAQ:IPCI)’s Analysts Are Bearish?

October 19, 2018 - By Adrian Erickson

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering IntelliPharmaCeutics International (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. IntelliPharmaCeutics International had 2 analyst reports since May 29, 2018 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 29 report. Below is a list of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) latest ratings and price target changes.

15/06/2018 Broker: Maxim Group Rating: Hold Old Target: $8 Terminates
29/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5000 Maintain

The stock decreased 0.92% or $0.0055 during the last trading session, reaching $0.5946. About 35,982 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 64.85% since October 19, 2017 and is downtrending. It has underperformed by 80.47% the S&P500.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $4.29 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: Benzinga.com which released: “Don’t Fixate On Market Woes, Just Make Your Trades” on October 12, 2018. Also Streetinsider.com published the news titled: “Intellipharmaceutics (IPCI) Prices 17.39M Unit Upsized Offering at $0.75/Unit” on October 12, 2018. Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Eiger’s Lymphoedema Drug Study Fails, Roche’s Sales Rise” with publication date: October 17, 2018 was also an interesting one.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>